Last updated: February 13, 2026
Overview of the Product
NDC 00024-5914 corresponds to Remdesivir, an antiviral medication approved by the U.S. Food and Drug Administration (FDA) for COVID-19 treatment. It is marketed under the brand name Veklury. Approved for hospitalized patients, Remdesivir has seen variable demand driven by infection rates, emerging variants, and evolving treatment protocols.
Production and Supply Dynamics
Remdesivir is manufactured primarily by Gilead Sciences. As of 2023, Gilead operates several manufacturing facilities globally, including a key plant in the U.S. that produces active pharmaceutical ingredients (API). Production capacity has increased since initial release; however, overall volume remains limited by complex synthesis processes and raw material procurement constraints.
Market Size and Usage
Global and U.S. Market
- Global COVID-19 treatments market (2022): Estimated at USD 20 billion, according to industry reports.
- U.S. market share (2023): Remdesivir accounts for roughly 65% of COVID-19 hospitalization antiviral treatments based on hospital procurement data.
- Demand trend: Following infection surges, demand fluctuates; recent declines in COVID-19 cases have reduced acute treatment needs.
Competition
- Alternatives: Pfizer’s Paxlovid, Merck’s Lagevrio (molnupiravir).
- Market penetration: Remdesivir maintains premium status due to regulatory approval for hospital use, but competition has eroded its market share from peak levels in early 2021.
Pricing Structure
Historical Pricing Data
- Initial federal contracts (2020): Gilead set the price at $520 per vial (10-day treatment course: 6 vials), equating to approximately $3,120 per treatment course.
- Commercial reimbursement: Varies; in the U.S., charged to insurers and hospitals with negotiated discounts.
Current Price Estimates (2023)
- List price: Roughly $520 per vial.
- Per treatment course: Approximately $3,120, assuming six vials per course.
- Discounts and negotiated rates: Actual costs to payers are often lower; estimates suggest net prices range from $1,200 to $2,400 per course, depending on volume agreements and procurement contracts.
Price Projections (Next 3-5 Years)
The following projections assume current trends, regulatory landscape, and competitive dynamics:
| Year |
Estimated Price Per Treatment Course |
Key Assumptions |
| 2023 |
$1,200 - $2,400 |
Demand stabilization, competitive pressure, reduced COVID-19 cases |
| 2024 |
$1,000 - $2,000 |
Pandemic transition, ongoing manufacturing efficiencies, potential patent or market exclusivity expiry concerns |
| 2025 |
$800 - $1,600 |
Increased generic manufacturing, further competition from new antivirals or biosimilars |
Note: Price declines are driven by market saturation, genericization, and regulatory changes.
Regulatory and Economic Factors Influencing Price
- Patent status: No patents on the API expired; Gilead holds method-of-use patents that could limit generic entry.
- Patent litigations: Ongoing patent disputes could affect genericization timelines.
- Government procurement policies: Public health agencies have negotiated lower prices through direct contracts.
- Reimbursement policies: Shifts toward value-based reimbursement models could influence net prices.
Key Considerations
- The role of Remdesivir in future pandemic preparedness plans could stabilize demand.
- The emergence of new antiviral therapies with superior efficacy or cost profiles could reduce demand and pricing.
- International markets exhibit varied pricing due to local health policies and economic constraints.
Key Takeaways
- The current list price of Remdesivir (NDC 00024-5914) is approximately $520 per vial; average treatment courses cost around $3,120.
- Net prices to payers are typically lower, influenced by discounts, procurement volume, and negotiations.
- Market size is primarily driven by COVID-19 hospitalizations, with demand declining as infection rates decrease.
- Price projections suggest a potential decrease to between $800 and $2,000 per treatment course over the next five years due to increased competition, generic entry, and market saturation.
- Regulatory factors, patent protections, and global demand will significantly shape future pricing dynamics.
FAQs
1. How does the arrival of generic Remdesivir impact pricing?
Generic entry would likely lower prices significantly, potentially by 50% or more, depending on manufacturing costs and market competition.
2. What factors could maintain higher prices for Remdesivir?
Limited alternative treatments, supply constraints, and ongoing pandemic needs, especially in emerging markets, could sustain higher prices.
3. Are there newer antivirals that threaten Remdesivir’s market share?
Yes, drugs like Paxlovid and Lagevrio have gained market share due to ease of oral administration and efficacy, potentially reducing demand for IV Remdesivir.
4. How do government contracts influence the final price?
Government negotiations often lead to discounted prices, typically lower than list prices, especially in bulk procurement.
5. What is the outlook for Remdesivir use outside COVID-19?
Current data does not indicate approved off-label uses; future research might explore broader antiviral applications.
References
- Gilead Sciences. "Veklury (Remdesivir) Product Information." 2023.
- IQVIA. "Global COVID-19 Treatment Market Report." 2022.
- U.S. Food and Drug Administration. "Remdesivir (Veklury) Approval and Updates." 2020-2023.
- Pharmaceutical Commerce. "Pricing and Reimbursement Trends for COVID-19 Treatments." 2023.
- MarketWatch. "Antiviral Drugs Market Analysis." 2022.
